» Articles » PMID: 12173334

Viral Load is a Significant Prognostic Factor for Hepatitis B Virus-associated Hepatocellular Carcinoma

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2002 Aug 14
PMID 12173334
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis B virus (HBV) is closely linked to hepatocellular carcinoma (HCC). The objective of the current study was to identify the factors involved in the prognosis of patients with HBV-associated HCC using multivariate analysis.

Methods: The current study included 74 patients with HBV-associated HCC who were admitted to Nagasaki University Hospital, Nagasaki, Japan, between 1983-1998. Of these, 13 patients underwent surgical tumor resection; 43 patients received nonsurgical treatment with transcatheter arterial embolization, percutaneous ethanol injection, or both; and 18 patients were followed without any active treatment. The significance of the patient's age; gender; history of blood transfusion; alcohol use; serum levels of alanine aminotransferase, alpha-fetoprotein, and HBV-DNA; number and size of liver tumors; clinical stage; and histologic diagnosis of HCC as prognostic factors was evaluated using univariate and multivariate analyses.

Results: The 3-year, 5-year, and 10-year postdiagnosis cumulative survival rates were 36%, 21%, and 17%, respectively. Multivariate analysis identified the level of serum HBV-DNA and tumor size at diagnosis as independent and significant prognostic factors (P = 0.0022 and P = 0.0106, respectively). In addition, a low level of viremia was found to be associated with longer survival (P = 0.0057) even in patients who were negative for the hepatitis B e antigen.

Conclusions: The results of the current study suggest that viral load is a useful prognostic marker for HBV-related HCC and that HCC patients with a less favorable course appear either to clear the virus poorly or to have a greater level of virus production.

Citing Articles

Preoperative Antiviral Therapy and Long-Term Outcomes for Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Liver Resection: A Multicenter Analysis.

Dai M, Liu S, Zhu L, Lu W, Xie G, Liang L J Hepatocell Carcinoma. 2024; 11:927-939.

PMID: 38803837 PMC: 11129739. DOI: 10.2147/JHC.S457135.


2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

J Liver Cancer. 2023; 23(1):1-120.

PMID: 37384024 PMC: 10202234. DOI: 10.17998/jlc.2022.11.07.


Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.

Wang P, Wang X, Liu X, Yan F, Yan H, Zhou D BMC Cancer. 2023; 23(1):564.

PMID: 37340357 PMC: 10280839. DOI: 10.1186/s12885-023-11059-y.


The urgency to expand the antiviral indications of general chronic hepatitis B patients.

Fan P, Li L, Chen E Front Med (Lausanne). 2023; 10:1165891.

PMID: 37275355 PMC: 10235492. DOI: 10.3389/fmed.2023.1165891.


2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Korean J Radiol. 2022; 23(12):1126-1240.

PMID: 36447411 PMC: 9747269. DOI: 10.3348/kjr.2022.0822.